AdventHealth

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials (2025) Lee MM, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, Mann JF, et al. Journal article Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial (2025) Mahaffey KW, Tuttle KR, Arici M, Baeres FM, Bakris G, Charytan DM, Cherney DZ, et al. Journal article Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) Badve SV, Bilal A, Lee MM, Sattar N, Gerstein HC, Ruff CT, McMurray JJ, et al. Journal article Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial (2024) Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JF, et al. Journal article Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (2024) Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, Baeres FM, et al. Journal article Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024) Mann JF, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, et al. Journal article Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis (2021) Mann J, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, Vilsboll T, et al. Journal article Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (2021) Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann J, Pratley R, Raz I, et al. Journal article Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) Buse JB, Bain SC, Mann J, Nauck MA, Nissen SE, Pocock S, Poulter NR, et al. Journal article Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) Verma S, Bain SC, Honoré JB, Mann J, A. Nauck M, E. Pratley R, Rasmussen S, et al. Journal article